KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Accumulated Expenses: 2018-2019

  • Amneal Pharmaceuticals' Accumulated Expenses fell 53.28% to $36.0 million in Q4 2019 from the same period last year, while for Dec 2019 it was $36.0 million, marking a year-over-year decrease of 53.28%. This contributed to the annual value of $36.0 million for FY2019, which is 53.28% down from last year.
  • Amneal Pharmaceuticals' Accumulated Expenses amounted to $36.0 million in Q4 2019, which was down 53.28% from $77.1 million recorded in Q4 2018.
  • Amneal Pharmaceuticals' Accumulated Expenses' 5-year high stood at $77.1 million during Q4 2018, with a 5-year trough of $36.0 million in Q4 2019.
  • Moreover, its 2-year median value for Accumulated Expenses was $56.5 million (2018), whereas its average is $56.5 million.
  • Data for Amneal Pharmaceuticals' Accumulated Expenses shows a maximum YoY crashed of 53.28% (in 2019) over the last 5 years.
  • Over the past 2 years, Amneal Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $77.1 million in 2018, then crashed by 53.28% to $36.0 million in 2019.